The GLP-1 Rebound: What Happens When the Meds Stop?

Weight-loss medications like Ozempic, Wegovy, and Mounjaro have completely changed the game. But they've also brought a major, frustrating challenge to light: what happens when you stop taking them?

Recent data shows that the weight doesn't just crawl back, it often rushes back:

               The Two-Thirds Rule: Major clinical trials show that after stopping these drugs, people regain an average of two-thirds (66%) of their lost weight within just one year. [1, 2]

               The Oxford Findings: A comprehensive 2026 review by researchers at the University of Oxford found that people who stop GLP-1 medications regain an average of nearly 22 pounds in the first year. [3]

               Back to Baseline: Most patients are projected to return entirely to their starting weight within 1.5 to 1.7 years after stopping. [3]

 

This isn't a failure of willpower. As anyone who has ever tried a traditional diet knows, "yo-yo dieting" has been the bane of our existence for decades.

 

Meet Your Biological Thermostat: The "Weight Set Point"

When you lose weight by eating less, whether through dieting, GLP-1 drugs, or simple calorie restriction, your metabolism naturally slows down. This is your body's ancient defense mechanism to protect its fat stores. In fact, studies have proven that GLP-1 medications directly lower your resting metabolic rate. [4, 5] This reaction is driven by what scientists call your "adipostat", also known as your weight set point.

Think of your weight set point like a home thermostat. If your house gets too hot, the AC kicks on; if it gets too cold, the heater starts up. Your body does the exact same thing to keep your weight within your biological "comfort zone." When your weight drops below this set point, your brain sounds the alarm. Believing you are starving, it triggers survival mode:

 

               1. It turns up the hunger dial by pumping out appetite-stimulating hormones (like ghrelin).

               2. It turns down the fullness dial by reducing hormones that make you feel satisfied (like leptin).

               3. It slows your metabolism, meaning you burn fewer calories doing basic, everyday tasks.

 

This makes keeping weight off feel like an uphill battle against your own biology.

 

The "Muscle Trap"

To make matters tougher, when you lose weight on GLP-1s, you don't just lose fat, you also lose lean muscle mass. If you stop the medication and the weight returns, your body prioritizes rebuilding its fat stores first. Without serious strength training and a high-protein diet, you risk regaining the weight as mostly fat, ultimately leaving you with a higher body fat percentage than when you started.

 

Your DNA and the Secret of "Brown Fat"

Why is this set point so stubborn? A huge part of it is written in your DNA. Genetics account for 40% to 70% of your weight variance, dictating your baseline metabolism and how sensitive your brain is to hunger signals. [6, 7] Specifically, your genetics control how good your body is at producing brown fat. Unlike regular white fat (which stores calories), brown fat acts like a furnace, actively burning calories to generate heat. Landmark studies published in the New England Journal of Medicine and elsewhere have shown that genetic struggles with creating brown fat are heavily linked to obesity. [8, 9]

 

A New Frontier: Can We Turn Up the Furnace?

Because your weight set point is heavily tied to how much energy your body burns, one promising approach to lasting weight loss may be turning up the furnace. If we can increase your body's energy expenditure, we may be able to lower your biological thermostat.

A necessary caveat before I describe our work: our investigational product candidate, EGS-2632, has been studied only in preclinical lab models and not yet in humans, is not approved by any regulatory authority, and there is no assurance it will prove safe or effective. Preclinical results may not translate to humans.

With that in mind, here is what we have seen so far at Energesis. In our lab studies, combining GLP-1 based weight loss with EGS-2632 produced much greater weight loss than GLP-1 treatment alone, an effect that was more than additive in these models. EGS-2632 created new brown fat and increased resting energy expenditure. The weight loss was also sustained for a prolonged period after dosing stopped, consistent with keeping the body's energy-burning engines running.

Our goal is to develop new, high-quality treatments that adjust the body's internal thermostat, with the hope of supporting deeper, healthier (fat-only) weight loss that is truly sustainable. Whether we can get there is exactly what further research, and ultimately clinical testing, will determine.

 

Sources

 

[1] Diabetes Obes Metab. 2022 Aug;24(8):1553-1564.

Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension

John P H Wilding 1, Rachel L Batterham 2 3 4, Melanie Davies 5 6, Luc F Van Gaal 7, Kristian Kandler 8, Katerina Konakli 8, Ildiko Lingvay 9, Barbara M McGowan 10, Tugce Kalayci Oral 8, Julio Rosenstock 11, Thomas A Wadden 12, Sean Wharton 13, Koutaro Yokote 14, Robert F Kushner 15; STEP 1 Study Group

 

[2] JAMA Netw Open. 2026 Mar 2;9(3):e263274.

Weight Changes With Tirzepatide and Concomitant Weight-Inducing Medications: Post Hoc Analysis of Randomized Clinical Trials

Rodolfo J Galindo 1, Kimberly A Gudzune 2, Michelle Look 3, Clare J Lee 4, Imane Benabbad 4, Dachuang Cao 4, Qier Meng 4, Donna Mojdami 4

PMID: 41885866

PMCID: PMC13022736

 

[3] BMJ. 2026;392:e085304.

Weight regain after cessation of medication for weight management: systematic review and meta-analysis.

West S, Scragg J, Aveyard P, et al.

 

[4] Cell Rep Med. 2025 Sep 16;6(9):102308. doi: 10.1016/j.xcrm.2025.102308

Can muscle avert GLP1R weight plateau and regain?

Dongdong Wang 1,2, Andre Djalalvandi 1,2, Christina T Saed 1,2, Katherine M Morrison 1,3, Gregory R Steinberg 1,2,∗

PMCID: PMC12490208  PMID: 40961927

 

[5] Diabetes Obes Metab. 2017 May 5;19(9):1242–1251. doi: 10.1111/dom.12932

Effects of once‐weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity

John Blundell 1,✉, Graham Finlayson 1, Mads Axelsen 2, Anne Flint 2, Catherine Gibbons 1, Trine Kvist 2, Julie B Hjerpsted 2

PMCID: PMC5573908  PMID: 28266779

 

[6] JAMA. 1986 Jul 4;256(1):51-4.

A twin study of human obesity

A J Stunkard, T T Foch, Z Hrubec

PMID: 3712713

 

[7] Front Endocrinol (Lausanne). 2012 Feb 28;3:29. doi: 10.3389/fendo.2012.00029

Variability in the Heritability of Body Mass Index: A Systematic Review and Meta-Regression

Cathy E Elks 1, Marcel den Hoed 1, Jing Hua Zhao 1, Stephen J Sharp 1, Nicholas J Wareham 1, Ruth J F Loos 1, Ken K Ong 1,2,*

PMCID: PMC3355836  PMID: 22645519

 

[8] N Engl J Med. 2015 Sep 3;373(10):895-907.

doi: 10.1056/NEJMoa1502214. Epub 2015 Aug 19.

FTO Obesity Variant Circuitry and Adipocyte Browning in Humans

Melina Claussnitzer 1, Simon N Dankel, Kyoung-Han Kim, Gerald Quon, Wouter Meuleman, Christine Haugen, Viktoria Glunk, Isabel S Sousa, Jacqueline L Beaudry, Vijitha Puviindran, Nezar A Abdennur, Jannel Liu, Per-Arne Svensson, Yi-Hsiang Hsu, Daniel J Drucker, Gunnar Mellgren, Chi-Chung Hui, Hans Hauner, Manolis Kellis

PMID: 26287746

PMCID: PMC4959911

 

[9] Cells (MDPI), April 2020

FTO Intronic SNP Strongly Influences Human Neck Adipocyte Browning Determined by Tissue and PPARγ Specific Regulation: A Transcriptome Analysis

Beáta B. Tóth, Rini Arianti, Abhirup Shaw, Attila Vámos, Zoltán Veréb, Szilárd Póliska, Ferenc Győry, Zsolt Bacso, László Fésüs, and Endre Kristóf

PMID: 32316277 / PMCID: PMC7227023